Physician profile
Joe Bradley
NPI 1700888799
$14,908.58
in general payments reported to CMS, 2019-2025
30 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,021 · 2020: $563 · 2021: $888 · 2022: $655 · 2023: $1,295 · 2024: $1,224 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $8,753.08 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $786.90 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $722.94 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $717.47 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $570.01 | 2019-2025 | Rexulti |
| Abbvie INC. | $393.07 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $340.20 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $290.29 | 2019-2020 | |
| Almatica Pharma LLC | $252.74 | 2023-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $241.28 | 2019-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $237.37 | 2019-2022 | |
| Alkermes, INC. | $232.02 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $217.29 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.35 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $167.37 | 2019-2025 | Spravato |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $128.53 | 2022-2023 | Dyanavel Xr |
| Corium, LLC | $108.35 | 2022-2024 | Azstarys |
| Noven Therapeutics, LLC | $95.97 | 2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $77.61 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $73.61 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $62.89 | 2019-2023 | Belsomra |
| Shire North American Group INC | $54.81 | 2019 | |
| Ironshore Pharmaceuticals INC. | $39.40 | 2019 | |
| Adlon Therapeutics L.P. | $30.71 | 2020-2021 | |
| Janssen Biotech, INC. | $24.38 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $22.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.67 | 2024 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $15.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.93 | 2019 | |
| Eisai INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.